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Summary
Several β cell antigens recognized by T cells in the non-obese diabetic (NOD)
mouse model of type 1 diabetes (T1D) are also T cell targets in the human
disease. While numerous antigen-specific therapies prevent diabetes in NOD
mice, successful translation of rodent findings to patients has been difficult.
A human leucocyte antigen (HLA)-transgenic mouse model incorporating
human β cell-specific T cells might provide a better platform for evaluating
antigen-specific therapies. The ability to study such T cells is limited by their
low frequency in peripheral blood and the difficulty in obtaining islet-
infiltrating T cells from patients.We have worked to overcome this limitation
by using lentiviral transduction to ‘reprogram’ primary human CD8 T cells
to express three T cell receptors (TCRs) specific for a peptide derived from
the β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP265–273) and recognized in the context of the human class
I major histocompatibility complex (MHC) molecule HLA-A2. The TCRs
bound peptide/MHC multimers with a range of avidities, but all bound with
at least 10-fold lower avidity than the anti-viral TCR used for comparison.
One exhibited antigenic recognition promiscuity. The β cell-specific human
CD8 T cells generated by lentiviral transduction with one of the TCRs
released interferon (IFN)-γ in response to antigen and exhibited cytotoxic
activity against peptide-pulsed target cells. The cells engrafted in HLA-A2-
transgenic NOD-scid IL2rγ null mice and could be detected in the blood,
spleen and pancreas up to 5 weeks post-transfer, suggesting the utility of this
approach for the evaluation of T cell-modulatory therapies for T1D and
other T cell-mediated autoimmune diseases.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease resulting
in part from the CD8 T cell-mediated killing of insulin-
producing pancreatic β cells. The non-obese diabetic
(NOD) mouse has been a widely used model of this disease
for many years [1]. Many autoantigens found to be targeted
by T cells in NOD mice have also been found to be targets
of T cells in the human disease [2]. Thus, the NOD mouse
has potential for testing therapies that eliminate antigen-
specific T cells or induce tolerance. However, while many
aspects of the pathogenesis of diabetes in NOD mice have
been elucidated and numerous treatments based on these
insights have prevented diabetes in mice [2,3], the disease
process in humans is more complex, and much remains
unknown [4]. Clinical trials based on rodent data have
shown only temporary and partial efficacy in a subset of
those treated [5,6]. An improved understanding of human
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diabetogenic T cells would help to ascertain more clearly
which antigen-specific therapies are likely to be successful.
The study of human diabetogenic T cells has been limited
by their low frequency in peripheral blood [7], the difficulty
in obtaining islets from T1D patients and the challenges
inherent in propagating islet-autoreactive T cell clones.
However, it is possible to ‘reprogram’ human T cells to
express a defined, new T cell receptor (TCR) using
retroviral or lentiviral transduction [8–12]. This strategy is
being used clinically to generate autologous antigen-specific
T cells against tumour or viral antigens in order to confer a
protective T cell response to patients [13]. Conversely, we
reasoned that human T cells redirected to recognize β cell
antigens could be transferred to an appropriate murine host
and used as targets for the development of antigen-specific
therapies for T1D.
The NOD-severe combined immunodeficiency (SCID)
IL2rγ null (NSG) mouse strain is a highly effective model for
the engraftment of both human haematopoietic stem cells
[14] and peripheral blood mononuclear cells (PBMC) [15].
The interleukin (IL)-2Rγ-chain deficiency eliminates the
residual natural killer (NK) cell activity present in NOD-
SCID mice that reduces engraftment efficiency [14]. As
these mice lack a competent immune system of their own,
particularly CD4 and CD8 T cells essential for disease devel-
opment, they cannot develop autoimmune diabetes [16].
However, they provide a potential system for the in-vivo
study of human autoreactive T cells. Transgenic NSG mice
have been developed to express the human class I major his-
tocompatibility complex (MHC) molecule HLA-A2 [17,18],
which is a T1D susceptibility allele in humans [19–21].
These NSG-A2 mice develop islet inflammation (insulitis)
when engrafted with PBMC from HLA-A2+ T1D patients
[22], demonstrating the potential use of this mouse model
for studying human β cell-specific T cells.
Islet-specific glucose-6-phosphatase catalytic-subunit
related protein (IGRP) is an antigen recognized by
autoreactive T cells in both NOD mice [23–25] and humans
[7,26–30]. The epitope IGRP265–273 (VLFGLGFAI), identical
in mice and humans, was first found to be recognized by
islet-infiltrating CD8 T cells in NOD mice transgenic for
HLA-A2 [31], and also shown later to be a target of CD8 T
cells in the peripheral blood [7,27,29] and islets [26] of
HLA-A2+ human T1D patients. We have generated lentiviral
vectors encoding three distinct human TCRs specific for
IGRP265–273/HLA-A2, two isolated from T1D patients and
one from a healthy donor. The TCRs were compared in vitro
by transduction of a TCR-deficient Jurkat cell line and were
found to vary in their avidity for peptide/MHC (pMHC)
multimers and to support antigen-specific responses to
varying degrees. Lentiviral transduction of primary human
CD8 T cells redirected them to be specific for the β cell
antigen IGRP, and to exhibit antigen-dependent cytokine
secretion and cytotoxic activity. After transfer into NSG-A2
mice, the transduced human CD8 T cells could be detected
in the blood, spleen and pancreas of recipient mice up to
5 weeks post-transfer. We propose NSG-A2 mice engrafted
with human β cell-specific T cells, generated by lentiviral
TCR transduction, as a new system for the study of human
autoreactive T cells and the development and testing of
antigen-specific therapies for T1D.
Materials and methods
Cells and cell culture
Human C1R [32] and T2 cells [33] were obtained from the
American Type Culture Collection (ATCC; Manassas, VA,
USA). C1R cells stably expressing HLA-A2 (C1R-A2) [34]
were obtained from V. Engelhard. Human Jurkat cells
expressing a chimeric class I MHC molecule consisting of
the α1 and α2 domains of HLA-A2 and the α3,
transmembrane and cytoplasmic portions of H-2Kb
(Jurkat-A2/Kb) [35] were provided by L. Sherman.
Jurkat/MA cells, a TCR-β chain-deficient Jurkat derivative
modified to express human CD8α and to contain a
luciferase reporter gene controlled by nuclear factor of acti-
vated T cells (NFAT) [36], were obtained from E. Hooijberg
and then modified further by lentiviral transduction to
increase human CD8α expression. All cell lines were main-
tained in Iscove’s modified Dulbecco’s medium (IMDM)
(Invitrogen, Grand Island, NY, USA) containing 10% heat-
inactivated fetal bovine serum (FBS) (Hyclone, Logan,
UT, USA) and penicillin/streptomycin (Invitrogen). For
lentiviral production, the 293T cell line [37] was used at
no more than 15 passages of a stock obtained from the
ATCC.
Cloning of the TCR-α and -β chains from human CD8
T cell clones specific for IGRP265–273/HLA-A2
CD8 T cells specific for IGRP265–273/HLA-A2 were cloned
from the peripheral blood of HLA-A*0201-positive T1D
patients (clones 7 and 32) or an HLA-A*0201-positive
healthy blood donor (clone FSB) and characterized as
described [29]. Following nomenclature of the international
ImMunoGeneTics information system (IMGT; http://
www.imgt.org), the TCR-α and -β chain gene usage of
clones 7, FSB and 32 was, respectively, TRAV41/TRAJ48/
TRBV6-2 (or -3)/TRBJ2-7; TRAV29/TRAJ29/TRBV28/
TRBJ2-7; and TRAV12-1/TRAJ48/TRBV20-1/TRBJ2-1. The
TCR-α and -β chains of each of the three T cell clones were
linked with the self-cleaving 2A peptide derived from
porcine teschovirus-1 by polymerase chain reaction (PCR),
as described previously [9], to allow equimolar expression
of both TCR chains [38]. The PCR product was then cloned
into a lentiviral transfer construct regulated by the spleen
focus-forming virus promoter [39] and followed by the 2A
peptide derived from Thoseassigna virus and the coding
sequence for green fluorescent protein (GFP). The transfer
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constructs encoding the control HLA-A2-restricted TCRs
1803 and 1·9 A2B, specific for HIV-1 p17gag77–85
(SLYNTVATL; SL9), have been described [9,40]. With the
exception of 1803, all TCR transfer constructs were codon-
optimized for expression in human cells [41].
293T cell transfection and lentiviral vector production
Lentiviral vectors were produced by calcium phosphate
transfection of 293T cells, as described previously [39].
Briefly, the transfer construct encoding the TCR-α–2A–
TCR-β sequence was co-transfected into 293T cells with
three additional plasmids: a packaging construct expressing
the gag and pol genes, a construct expressing rev and a
construct expressing the VSV-G envelope. Culture superna-
tant was replaced 16 h after transfection and lentiviral
supernatant was collected 24 and 48 h later and passed
through a 0·22 μm filter. Lentivirus was concentrated by
ultracentrifugation, resuspended in sterile PBS and frozen
in aliquots at −80°C until use. Viral titres ranged from 3 to
11 × 109 transducing units/ml.
Jurkat/MA cell transduction and lentiviral titring
Jurkat/MA cells [36] were transduced in complete IMDM
containing 4 μg/ml polybrene in 24-well plates (1 × 105 cells/
well in 500 μl). After the addition of an infectious dose of
lentivirus sufficient to obtain greater than 95% transduction,
the plates were centrifuged at 1350 g for 30 min. Cells were
incubated for 16 h at 37°C and 500 μl fresh medium without
polybrene was added. Transduced cells were cultured an
additional 3–5 days before checking transduction efficiency
by flow cytometry. Additionally, lentivirus was quantified by
titring in Jurkat/MA cells. For this, cells were plated into six-
well plates (1 × 105 cells/well) and transduced with 10-fold
serial dilutions of lentivirus. Transduction efficiency was
determined by flow cytometric analysis of GFP expression.
Titre was determined from the viral dilution that gave GFP
expression in 1–10% of cells [39].
Primary human T cell transduction
PBMC were isolated from HLA-A2+ leucopacks from
anonymous donors (New York Blood Center) by Ficoll
density gradient centrifugation. HLA-A2 expression was
determined by flow cytometry using a fluorescein
isothiocyanate (FITC)-conjugated anti-HLA-A2-specific
antibody (BB7·2; BD Biosciences, San Jose, CA, USA). For
some experiments, cryopreserved HLA-A2+ PBMC were
obtained from AllCells (Alameda, CA, USA). CD8 T cells
were isolated from PBMCs by positive selection with
Miltenyi magnetic beads and cultured in RPMI-1640
(Invitrogen) containing 10% heat-inactivated FBS
(Hyclone), penicillin/streptomycin (Invitrogen), non-
essential amino acids (Invitrogen) and sodium pyruvate
(Invitrogen). Prior to transduction, CD8 T cells were acti-
vated with 30 ng/ml anti-CD3 (OKT3; eBioscience, San
Diego, CA, USA) and 1 μg/ml anti-CD28 (CD28·2; BD
Biosciences) for 2 days and 50 U/ml of recombinant human
(rh)IL-2 (Peprotech, Rocky Hill, NJ, USA) for 1 day. Cells
were transduced with lentivirus at a multiplicity of infec-
tion of ≥ 50 in 24-well plates (5 × 105 cells/well in 500 μl) in
the presence of 8 μg/ml polybrene while being centrifuged
at 1350 g for 1 h. The next day an equal volume of complete
medium with 50 U/ml IL-2 was added, and cells were cul-
tured for 2–5 days before monitoring transduction effi-
ciency by flow cytometry.
Analysis of transduced cells by flow cytometry
Transduced Jurkat/MA and primary human CD8 T cells were
stained for 30 min on ice with an antibody to human
TCR-αβ (T10B9·1A-31; BD Biosciences) as well as with anti-
bodies to human TCR-β chain variable regions: anti-Vβ2-
phycoerythrin (PE) (MPB2D5; Beckman Coulter, Brea, CA,
USA), anti-Vβ3-RPE (JOVI-3; Ancell, Bayport, MN, USA)
and anti-Vβ13·2-PE (H132; eBioscience). TCR-Vα2 was
detected using anti-Vα2 (F1; Pierce, Rockford, IL, USA) and
rat anti-mouse IgG2a-allophycocyanin (344701; R&D
Systems, Minneapolis, MN, USA). Transduced Jurkat/MA
cells were stained with HLA-A2/IGRP265–273 or HLA-A2/SL9
tetramer-PE at 34 nM for 1 h at room temperature. To evalu-
ate tetramer staining, gates were set based on unstained con-
trols. Transduced primary human CD8 T cells were stained
with HLA-A2/IGRP265–273 or HLA-A2/SL9 dextramer-
allophycocyanin (Immudex, Copenhagen, Denmark) for
10 min at room temperature according to the manufacturer’s
recommendations. To evaluate dextramer staining, gates were
set based on the irrelevant dextramer controls. In certain
experiments, cells were pretreated with 50 nM dasatinib
(Axon Medchem, Groningen, the Netherlands) for 1 h at
37°C, followed by tetramer or dextramer staining in the pres-
ence of dasatinib. For detection of granzyme B, cells were
treated with 1 × fixation and permeabilization buffer
(eBioscience) and anti-granzyme B-AlexaFluor 700 (GB11;
BD Biosciences). 4’,6-Diamidino-2-phenylindole (DAPI;
Sigma-Aldrich, St Louis, MO, USA) was added just prior to
acquisition on a BD LSRII flow cytometer, allowing for the
exclusion of dead cells from further analysis. Data were ana-
lysed with FlowJo software (Tree Star Inc., Ashland, OR,
USA).
Jurkat/MA cell luciferase assay
T2 [33], C1R [32], C1R-A2 [34], Jurkat-A2/Kb [35] or
splenic dendritic cells (DCs) from HLA-A2-transgenic
NOD.β2mnull.HHD mice [31] were loaded with the HIV gag
peptide SL9 or IGRP265–273 for 1 h at 26°C. An equal number
of transduced Jurkat/MA cells (generally greater than 95%
GFP+, as determined by flow cytometry) were added and
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cells were co-cultured for 16 h at 37°C. In certain experi-
ments, T2 cells were loaded with peptide for 30 min at
26°C, and then treated with 5, 10 or 20 μg/ml HLA-A2
blocking antibody (BB7·2; BD Biosciences) for 30 min at
26°C before the addition of Jurkat/MA cells. The cells were
washed with PBS, then lysed with Reporter Lysis Buffer
(Promega, Madison, WI, USA) and frozen at −80°C and
then thawed to complete lysis. Luciferase activity was meas-
ured using the Promega Luciferase Assay System. Lumines-
cence was measured using a Victor plate reader.
Determination of tetramer avidity
Jurkat/MA cells were transduced with TCRs 1803, 7, FSB
and 32 and sorted by fluorescence-activated cell sorting
(FACS) as needed to generate cells with comparable levels
of TCR expression with a FACSAria. Equivalent numbers of
GFP+ cells were stained with HLA-A2/IGRP265–273
tetramer-PE serial dilutions of 34, 17, 8·5, 4·25 and
2·125 nM in 25 μl FACS buffer (1% FBS, 0·1% sodium azide
in PBS) for 1 h at room temperature. Cells were washed
once with 200 μl FACS buffer and then resuspended in
200 μl 1% paraformaldehyde. Data were collected using a
BD LSRII flow cytometer and analysed with FlowJo soft-
ware (Tree Star). GFP+ cells were gated on for analysis of
tetramer staining. To determine the avidity of tetramer
binding to each TCR, non-linear regression analysis of
tetramer concentration versus tetramer-PE mean fluores-
cence intensity (MFI) was performed using GraphPad
Prism software. The MFI of unstained cells was subtracted
from all values when assessing tetramer avidity.
Human interferon (IFN)-γ enzyme-linked immunospot
(ELISPOT) assay
T2 cells were plated at 5 × 104 cells/well in 50 μl complete
RPMI in a 96-well multi-screen filter plate (Millipore,
Billerica, MA, USA) precoated with anti-IFN-γ antibody
(MAB285; R&D Systems) and blocked with 1% bovine
serum albumin (BSA), and loaded with 10 μM peptide SL9
or IGRP265–273 for 1 h at 26°C. Transduced human CD8 T
cells and untransduced control cells were added at 5 × 104
cells/well in 50 μl complete RPMI and incubated for 40 h.
IFN-γ was detected with a second, biotinylated anti-IFN-γ
antibody (BAF285; R&D Systems), and spots were devel-
oped using streptavidin–alkaline phosphatase (Zymed
Laboratories, Carlsbad, CA, USA) and 5-bromo-4-chloro-3-
indolyl-phosphate/nitro-blue tetrazolium (NBT) substrate
(Sigma-Aldrich). Spots were counted by an automated
ELISPOT reader system (Autoimmun Diagnostika,
Strasberg, Germany).
Lactate dehydrogenase (LDH) cytotoxicity assay
T2 cells were plated in 96-well round-bottomed plates at
2 × 104 cells/well in 50 μl RPMI with 5% FBS and loaded
with 10 μM SL9 or IGRP265–273 peptide for 1 h at 26°C.
Transduced human CD8 T cells and untransduced controls
were added at effector : target ratios of 10 : 1 and 2·5 : 1 in
50 μl RPMI with 5% FBS. Cells were co-cultured for 4 h at
37°C, centrifuged, and lactate dehydrogenase (LDH) was
detected in the supernatant using an LDH Cytotoxicity
Assay Kit (Pierce). Percentage of cytotoxicity was calculated
as 100 × (measured reading – effector only – target only)/
(target maximum lysis – target only).
Engraftment of transduced human CD8 T cells in
NSG-A2 mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A2·1)1Enge/SzJ (NSG-
A2) mice [18] were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). Human HLA-A2+ CD8 T cells were
transduced with lentiviral vectors as described above. Four
days later, 4 × 106 cells were combined with 8 × 106 CD8 T
cell-depleted PBMC from the same donor and transferred
via tail vein into NSG-A2 mice. The CD8 T cell-depleted
PBMC had been activated with anti-CD3, anti-CD28 and
IL-2 and maintained in culture until use, as described above
for the transduced CD8 T cells. Blood was taken weekly
from the tail of the mice starting at week 1 and analysed for
engraftment by flow cytometry. At week 5 mice were
euthanized, and blood, spleen and pancreas were analysed
for engraftment by flow cytometry. Cells were stained with
anti-human CD45-V450 (HI30; BD Biosciences), anti-
human CD8-allophycocyanin-cyanine 7 (Cy7) (RPA-T8;
BD Biosciences), anti-human CD4-peridinin chlorophyll
(PerCP)-Cy5·5 (L200; BD Biosciences), allphycocyanin-
labelled HLA-A2/IGRP265–273 or HLA-A2/SL9 dextramers
(Immudex), anti-mouse CD45-PE-Cy7 (30-F11; BD
Biosciences) and LIVE/DEAD Fixable Yellow (Invitrogen)
prior to fixing with 1% paraformaldehyde. NSG-A2 mice
that did not receive human cells were used as negative con-
trols for identifying the human CD45+ population, and
human PBMC were used as single-stained controls for the
anti-human antibodies. All animal studies were approved by
Albert Einstein College of Medicine’s Institutional Animal
Care and Use Committee.
Results
Lentiviral transduction of TCR-deficient
Jurkat/MA cells
The TCR-α and -β chains from three distinct human T
cell receptors specific for HLA-A2/IGRP265–273 were linked
with a self-cleaving viral 2A sequence to achieve equimolar
expression of both TCR chains [38] and inserted into a
lentiviral vector regulated by the spleen focus-forming
virus promoter. Despite their common specificity, the α
and β chains of the TCRs utilized different Vα and Vβ
gene segments (Table 1). However, sequence analysis of the
J. Babad et al.
4 © 2014 British Society for Immunology, Clinical and Experimental Immunology
Human b cell-specific CTL made by lentiviral transduction
VC 2014 British Society for Immunology, Clinical and Experimental Immunology, 179: 398–413 401
complementarity determining regions (CDRs) revealed
several common residues, particularly in the CDR3α
sequences of TCRs 7 and 32, and the CDR3β sequences of
TCRs 7 and FSB.
Expression of the lentivirus-encoded TCRs was evaluated
by transducing the CD8+ TCR-β-deficient cell line
Jurkat/MA [36], which does not express endogenous TCR
on its surface. Transduction with lentiviral vectors 7, FSB
and 32 resulted in the expression of vector-encoded GFP
and TCR in greater than 95% of the cells (Fig. 1a). To
further characterize the TCRs, transduced cells were stained
with TCR Vβ-specific antibodies (Fig. 1a). Vβ staining was
comparable to TCR staining, as nearly all GFP+ cells also
stained with the Vβ antibody specific for that TCR (i.e.
Vβ13·2 for 7, Vβ3 for FSB and Vβ2 for 32). While Vα anti-
bodies specific for TCRs 7 and FSB were not available, we
were able to verify co-expression of the lentivirus-encoded
TCR-α and -β chains of TCR 32 by co-staining transduced
Jurkat/MA cells with antibodies specific for Vα2 and Vβ2
(Fig. 1b). Note that the TCR nomenclature used to desig-
nate commercial anti-Vα and -Vβ antibodies is according
to Arden [42], and differs from the IMGT nomenclature
provided in the Materials and methods.
Tetramer staining of transduced Jurkat/MA cells reveals
varying avidities for pMHC among the three TCRs
To verify the specificity of the transduced TCRs for IGRP265–
273, transduced Jurkat/MA cells were stained with
PE-labelled HLA-A2/IGRP265–273 tetramers (Fig. 2a). All
three TCRs were stained successfully with the tetramers,
although with varying intensities. TCR 32 stained very
brightly, while FSB stained moderately well and 7 stained
weakly, with little separation between positive and negative
cells. Tetramer staining has been shown to be correlated
with TCR/pMHC monomer affinity [43,44]. To verify that
the weak tetramer staining of TCRs 7 and FSB was due to
low-affinity binding and not the result of the transduced
TCR-β chain pairing with the endogenous Jurkat/MA
TCR-α chain, transduced cells were pretreated with the
protein kinase inhibitor dasatinib prior to tetramer stain-
ing. Dasatinib has been shown to improve the tetramer
staining of low-affinity TCRs by preventing TCR internali-
zation that occurs during tetramer staining and by reducing
tetramer-induced cell death [45]. Dasatinib pretreatment of
transduced cells resulted in substantial improvements in
tetramer staining for all three TCRs (Fig. 2a,b). The most
significant effect was seen with TCRs 7 and FSB, for which
distinct tetramer-positive populations were now observed.
As TCR 32-transduced cells already stained well with
tetramer, the effect was less dramatic, resulting in only a
slightly higher intensity of staining. These results indicated
that the weaker tetramer staining of TCRs 7 and FSB was
due probably to a lower-affinity TCR/pMHC interaction.
Dasatinib pretreatment did not cause an increase in non-
specific binding to a negative control HLA-A2/SL9 tetramer
(Fig. 2b).
To investigate further these differences in tetramer stain-
ing intensities, transduced cells were stained with serial
dilutions of the tetramers, and equilibrium binding results
were used to determine the avidity of tetramer binding to
each TCR. Binding was carried out for 1 h, as staining
intensity was increased only minimally beyond this time-
point (Fig. 2c). Because the observed avidity of tetramer
binding could be influenced by the expression level of both
CD8 and TCR, transduced Jurkat/MA cells were FACS-
sorted as needed to generate cells with equivalent TCR
expression. These sorted cells expressed comparable levels
of both CD8 and TCR (Fig. 2d). As suggested by the initial
tetramer staining, of the three IGRP TCRs, TCR 32 bound
the most avidly to the HLA-A2/IGRP265–273 tetramer, exhibit-
ing a tetramer avidity of 16 ± 8 nM, compared to
124 ± 42 nM for FSB and 97 ± 14 nM for TCR 7 (Fig. 2e).
As expected, the HIV-specific TCR 1803 bound more avidly
to its cognate tetramer (1·8 ± 0·4 nM) than did any of the
IGRP-specific TCRs (Fig. 2e).
Table 1. Amino acid comparison of human islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)265–273-specific T cell receptor
(TCR)-α and -β chains.
(a) TCR-α chain CDRs*
TCR Vα† CDR1α CDR2α CDR3α
7 Vα19 VGISA LSSGK AVTSNFGNEKLT†
FSB Vα21 NSMFDY ISSIKDK AASAGSGNTPLV
32 Vα2 NSASQS VYSSGN VVNILSNFGNEKLT
(b) TCR-β chain CDRs*
TCR Vβ† CDR1β CDR2β CDR3β
7 Vβ13·2 MNHEY SVGEGT ASSSRFVGEGLFRYGYEQY
FSB Vβ3 MDHEN SYDVKM ASSSISGYEQY
32 Vβ2 DFQATT SNEGSKA SASRQGWVNEQF
*Underlined letters indicate amino acid identity among the TCRs. †According to Arden. [42].
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Fig. 1. Lentiviral transduction of T cell receptor
(TCR)-deficient Jurkat/MA cells. (a) Jurkat/MA
cells were transduced with lentiviruses encoding
the indicated islet-specific
glucose-6-phosphatase catalytic subunit-related
protein (IGRP)265–273-specific TCRs and
evaluated for TCR expression 4 days after
transduction. Cells were stained with
anti-human TCR and anti-Vβ antibodies
specific for the three TCRs. (b) As in (a), except
that an anti-Vα antibody specific for TCR 32
was also included.
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Lentivirus-encoded TCRs support signalling in
Jurkat/MA cells to varying degrees
In addition to its TCR deficiency, the Jurkat/MA cell line
expresses luciferase under the control of the TCR-induced
transcription factor NFAT [36]. In order to test the func-
tional activity of the three lentivirus-encoded TCRs, we
measured the luciferase activity of the transduced
Jurkat/MA cells in response to 1 μM IGRP265–273 presented
by the human HLA-A2+ cell line T2 [33] (Fig. 3a).
Jurkat/MA cells transduced to express the 1803 TCR [46],
specific for the HIV gag epitope SL9, were also used in these
experiments. The FSB TCR responded to its cognate
peptide, although not as strongly as did the HIV TCR 1803,
which has a much higher avidity for its pMHC. TCR 7 did
not give a detectable response to IGRP265–273. Unexpectedly,
TCR 32 responded strongly to T2 cells, regardless of
whether or not an exogenous peptide was provided.
To correlate further the TCR binding avidity results with
functional activity, we performed a dose–response luciferase
experiment using the TCR-equalized transduced Jurkat/MA
cells (Fig. 3b). Cells transduced with the high-avidity TCR
1803 maintained a strong luciferase response to the SL9
peptide, even at 0·01 μM. The lower-avidity FSB TCR
responded to IGRP265–273 at concentrations of 1 μM and
above. TCR 7 did not have an observable response, even at
100 μM peptide. TCR 32 continued to demonstrate a non-
specific response to the T2 cells, which was unaffected even
with high concentrations of IGRP265–273. To verify that these
were HLA-A2-restricted responses, T2 cells were loaded
with peptide, then treated with an HLA-A2 blocking anti-
body prior to the addition of Jurkat/MA cells (Fig. 3c). At
20 μg/ml blocking antibody, responses from TCRs FSB and
32 were nearly abolished, while 1803 maintained a reduced
but robust response. TCR 32 also responded in varying
degrees to other HLA-A2+ human cell lines tested as
antigen-presenting cells (APC), including C1R-A2 [34] and
Jurkat-A2/Kb [35], although it did not respond to the HLA-
A2− cell line C1R [32] (Fig. 3d). These results suggest that,
in addition to recognizing HLA-A2/IGRP265–273, TCR 32 also
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Fig. 2. Human T cell receptors (TCRs) specific
for islet-specific glucose-6-phosphatase catalytic
subunit-related protein (IGRP)265–273
demonstrate varying avidity for peptide/major
histocompatibility complex (MHC) tetramers.
(a) Jurkat/MA cells were transduced with
lentiviruses encoding the indicated TCRs and
stained with human leucocyte antigen
(HLA)-A2/IGRP265–273 tetramers alone (−D) or
following treatment with 50 nM dasatinib (+D).
(b) Transduced cells were stained with
HLA-A2/SL9 (upper panel) or
HLA-A2/IGRP265–273 tetramers (lower panel)
with (not shaded) or without (shaded) 50 nM
dasatinib pretreatment. Dasatinib pretreatment
improves tetramer staining of low-affinity TCRs
but does not increase non-specific tetramer
staining. (c) To determine the time required for
IGRP tetramer staining to reach equilibrium,
transduced Jurkat/MA cells were stained with
IGRP tetramer for 30, 60, 90 or 120 min at
room temperature and analysed by flow
cytometry. (d) Transduced Jurkat/MA cells were
sorted by fluorescence-activated cell sorting
(FACS) for equivalent TCR levels and evaluated
for CD8 (left panel) and TCR expression (right
panel). (e) The avidity of the TCR/tetramer
interaction was determined by staining
TCR-equalized Jurkat/MA cells with serial
dilutions of HLA-A2/IGRP265–273 tetramers and
performing non-linear regression analysis. The
mean fluorescence intensity (MFI) of unstained
cells was subtracted from all values when
assessing tetramer avidity. The graph shown is
representative of three separate experiments.
Values below the graph are mean ± standard
deviation of the three experiments.
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cross-reacts with a second peptide presented in the context
of HLA-A2 by the three human cell lines examined. This
idea is supported by the finding that Jurkat-A2/Kb, which
expresses less than half as much HLA-A2 on its surface as
T2 and C1R-A2 (data not shown), elicited a weaker
response from TCR 32 than did the other two cell lines.
Similarly, when DCs from mice transgenic for HLA-A2
(Fig. 3e) were used as the APC, the response of TCR 32 in
the absence of exogenous peptide was reduced compared to
that observed with the human HLA-A2+ cell lines. These
reductions in IGRP peptide-independent signalling were
sufficient to allow a modest response of TCR 32 to IGRP265–
273 to be observed (Fig. 3d,e). When DCs were used as the
APC, TCRs 7 and FSB also responded to IGRP265–273
although, like 32, TCR 7 responded only to the highest con-
centration of peptide (100 μM) (Fig. 3e). Taken together,
these experiments demonstrate the differing functional
activities of the lentivector-encoded TCRs 7, FSB and 32 in
transduced Jurkat/MA cells and suggest TCR FSB as the best
candidate for the in-vivo aspects of our work.
Reprogramming human primary CD8 T cells with
IGRP-specific TCRs
We next sought to evaluate the ability of the lentiviral
vectors to transduce primary cells and to confirm FSB as the
most useful of the three IGRP-specific TCRs. CD8 T cells
were purified from peripheral blood of HLA-A2+ human
donors, activated to increase transduction efficiency, and
transduced separately with the three lentiviral vectors.
Transduction efficiency was determined by flow cytometric
analysis of GFP expression and staining with the appropri-
ate TCR Vβ-specific antibodies (Fig. 4a). Untransduced
cells lacked GFP expression, but had variable levels of
endogenous expression of Vβ2, Vβ3 and Vβ13·2 TCRs.
Transduction efficiencies varied depending on the donor,
but ≥ 90% of GFP+ cells were found consistently to express
the lentiviral-encoded TCR-β chain. Additionally, the inten-
sity of Vβ staining was comparable to endogenous levels,
indicating that the transduced TCRs were being expressed
at normal levels. To verify the proper pairing of the
transduced TCR chains, cells were pretreated with dasatinib
and stained with HLA-A2/IGRP265–273 dextramers [47],
pMHC multimers demonstrated to enable improved detec-
tion of low-affinity TCRs compared to standard tetramers
[48]. Human primary CD8 T cells transduced with TCRs
FSB and 32 both stained with the dextramers (Fig. 4b),
although no staining was detected in the case of TCR 7. As
primary human CD8 T cells have endogenous TCR expres-
sion, it is likely that there is some mixed pairing of
transduced TCR-α and -β chains with endogenous chains,
resulting in reduced expression of the lentivirus-encoded
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Fig. 3. Lentivirus-encoded T cell receptors
(TCRs) are functional in Jurkat/MA cells. (a) T2
cells were preincubated with 1 μM SLYNTVATL
(SL9) or islet-specific glucose-6-phosphatase
catalytic subunit-related protein (IGRP)265–273
for 1 h before addition of Jurkat/MA cells
transduced with lentiviruses encoding the
indicated TCRs. After overnight co-culture,
luciferase activity was measured. Graph depicts
mean ± standard deviation (s.d.) of seven
independent experiments. U, untransduced
Jurkat/MA cells; **P < 0·005. (b) As in (a),
except T2 cells were preincubated with 10-fold
serial dilutions of SL9 or IGRP265–273 from
0·01 μM to 100 μM. (c) As in (a), except after
30 min incubation with 1 μM SL9 or
IGRP265–273, T2 cells were treated with 5, 10 or
20 μg/ml human leucocyte antigen (HLA)-A2
blocking antibody before addition of
transduced Jurkat/MA cells. (d) As in (a), except
that the indicated cell lines were used as
antigen-presenting cells (APC) and 10 μM
peptide was used. Graph depicts mean ± s.d. of
technical replicates. *P < 0·05; **P < 0·005;
***P < 0·0001. (e) As in (a), except that splenic
dendritic cells (DCs) from non-obese diabetic
(NOD).β2mnull.HHD mice were used as APC.
Graph depicts mean ± s.d. of technical
replicates. *P < 0·05; **P < 0·01; ***P < 0·005;
****P < 0·0001.
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TCR and lower pMHC multimer staining than observed in
the case of transduced Jurkat/MA cells (Fig. 2a).
FSB-transduced human CD8 T cells release IFN-γ in
response to their cognate antigen and lyse
peptide-pulsed target cells
After demonstrating that human primary CD8 T cells could
be engineered to express β cell-specific TCRs, we next
examined the effector functions of the transduced cells. To
do this, transduced cells were co-cultured with T2 cells pre-
treated with IGRP265–273, and their response was measured by
IFN-γ ELISPOT (Fig. 5a). In agreement with the luciferase
results obtained with transduced Jurkat/MA cells, IFN-γ
production by FSB-transduced primary human CD8 T cells
was the most pronounced. TCR 7 trended towards an
increase in IFN-γ-producing cells in the presence of T2 cells
loaded with IGRP265–273, but this was not significantly differ-
ent from the response to an irrelevant peptide or to T2 cells
alone. TCR 32-transduced cells did not show a specific
response to IGRP265–273-loaded T2 cells.
To evaluate further the ability of the transduced CD8 T
cells to act as cytotoxic T lymphocytes (CTL), an LDH
release assay was performed to measure their cytotoxic
activity. T2 cells loaded with IGRP265–273 were specifically
lysed by FSB-transduced cells compared to T2 cells loaded
with the irrelevant SL9 peptide (Fig. 5b). Cells transduced
with the SL9-specific TCR 1·9 A2B lysed SL9-loaded T2
cells, but not IGRP265–273-loaded T2 cells. In contrast to TCR
FSB, cells transduced with TCRs 7 or 32 did not exhibit spe-
cific lysis of IGRP265–273-pulsed target cells (data not shown).
Taken together, these experiments demonstrate successful
transduction of primary human CD8 T cells with IGRP-
specific TCRs, with FSB yielding cells possessing peptide-
specific CTL functions including IFN-γ production and
cytotoxic activity. TCR FSB is clearly the preferred TCR for
in-vivo studies, given that it responds in a dose-dependent
manner to peptide concentrations as low as 1 μM
(Fig. 3a,b). Furthermore, primary human T cells transduced
to express FSB show cytotoxic activity against peptide-
pulsed target cells in vitro even at low effector : target ratios
(Fig. 5b).
Long-term survival of engrafted transduced cells in
NSG-A2 mice
In-vivo studies of the autoimmune activity of the TCR-
transduced human CD8 T cells would require long-term
engraftment in NSG-A2 hosts. It has been shown that intra-
venous injection of at least 1 × 107 PBMC yields the best
engraftment outcome in NSG mice [15]. As CD8 T cells
have been found to engraft poorly in NOD-SCID mice
when transferred alone [49], we injected NSG-A2 mice
intravenously with 4 × 106 untransduced or FSB-transduced
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Fig. 4. Lentiviral transduction can be used to generate human β cell-specific CD8 T cells. Primary human CD8 T cells were transduced with
lentiviruses encoding the indicated T cell receptors (TCRs) and (a) stained with anti-Vβ antibodies specific for each of the three TCRs or (b)
pretreated with 50 nM dasatinib and stained with human leucocyte antigen (HLA)-A2/ islet-specific glucose-6-phosphatase catalytic subunit-related
protein (IGRP)265–273 or human leucocyte antigen (HLA)-A2/SLYNTVATL (SL9) dextramers. Plots shown in (b) are from the green fluorescent
protein (GFP)+ gate.
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human CD8 T cells in combination with 8 × 106 CD8 T
cell-depleted PBMC from the same donor. Blood
engraftment levels were monitored weekly, and at 5 weeks
after transfer mice were euthanized to examine spleen and
pancreas engraftment as well. The experiments were termi-
nated at 5 weeks, because xenogeneic graft-versus-host
(GvH) disease occurs in NSG mice repopulated with PBMC
between 30 and 45 days post-transfer [15,50]. The level of
engraftment of hCD45+ cells in mice receiving FSB-
transduced CD8 T cells was similar to engraftment in mice
receiving untransduced cells (Table 2). The percentage of
engrafted cells in the blood increased each week, and higher
engraftment was seen in the spleen than in the blood.
Human CD45+ cells were also observed in the pancreata of
both untransduced and FSB-transduced recipient mice.
Recipients that received untransduced cells tended to have a
higher percentage of engrafted CD8 T cells, but this was
only statistically significant at the 3-week time-point. In
FSB-transduced recipient mice, GFP+ CD8 cells could be
detected as early as 2 weeks after transfer, and remained
detectable in blood, spleen and pancreas 5 weeks after
transfer (Fig. 6a; Table 2). Histological analysis of pancreas
sections revealed mild infiltration around some islets in
both untransduced and FSB-transduced recipient mice
(Fig. 6b) due probably, at least in part, to a GvH response to
murine class I MHC molecules [15,50]. Because of this
non-specific infiltration, we were unable to discern a differ-
ence in histopathology between the two groups, and diabe-
tes was not observed in any of the recipients during the
5-week experimental period. To evaluate whether the
transduced cells maintained their CTL capabilities after
engraftment, splenocytes from untransduced, FSB-
transduced and 1803-transduced recipients were analysed 5
weeks after engraftment for granzyme B expression
(Fig. 6c). In all mice tested, granzyme B expression was
restricted to the CD8 T cell population. Importantly,
granzyme B expression in GFP+ FSB and 1803-transduced
cells was comparable to granzyme B expression of
GFP− cells in the same host, as well as those from
untransduced recipients. This result confirms that the
transduced human cells retain CTL function after 5 weeks
in the mouse host.
Discussion
The NOD mouse has been the prevailing model for the
study of T1D for many years and has greatly improved our
understanding of this autoimmune disease [1]. However,
while the disease can be prevented, and even reversed, in the
mice [2,3], a robust immunological therapy for human T1D
has not yet been achieved [5,6]. We reasoned that the ability
to investigate the impact of therapeutic approaches target-
ing human β cell-specific T cells might support the transla-
tion of rodent data to the human disease. To that end, we
have used lentiviral transduction to generate human CD8 T
cells specific for IGRP265–273/HLA-A2. Cells transduced with
TCR FSB exhibited characteristics of CTL, including
antigen-dependent IFN-γ secretion and lysis of peptide-
pulsed targets, suggesting in-vitro uses for such cells, e.g.
investigation of mechanisms of β cell killing by human T
cells or antigen identification in the case of β cell-specific
TCRs of unknown specificity. Importantly, the transduced
cells survived for up to 5 weeks in NSG-A2 hosts and will
thus permit the future evaluation of T cell-modulatory
interventions in an in-vivo system that incorporates human
T cells interacting with human MHC molecules. Although
TCR-transduced human T cells have been used to achieve
anti-tumour or anti-viral activity in patients [13], their
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Fig. 5. T cell receptor (TCR)-transduced primary human CD8 T cells
release interferon (IFN)-γ and are cytotoxic. (a) Primary human CD8
T cells were transduced with lentiviruses encoding the indicated TCRs
and incubated with T2 cells loaded with 10 μM SLYNTVATL (SL9) or
islet-specific glucose-6-phosphatase catalytic subunit-related protein
(IGRP)265–273. IFN-γ production was detected by enzyme-linked
immunospot (ELISPOT). Graph depicts mean ± standard deviation
(s.d.) of three independent experiments. **P < 0·005. (b) Transduced
primary human CD8 T cells were incubated with peptide-loaded T2
cells at an effector : target (E : T) ratio of 10 : 1 or 2·5 : 1. Cytotoxicity
was measured by lactate dehydrogenase (LDH) release into the
supernatant. Graph depicts mean ± s.d. of technical replicates. U,
untransduced primary human CD8 T cells; *P < 0·05; **P < 0·005.
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long-term survival and utility in immune-deficient murine
models has not been reported previously.
In the course of developing this system, we first character-
ized three human TCRs specific for IGRP265–273/HLA-A2 in
terms of their structural and functional avidities. As deter-
mined by measurement of tetramer avidity values, the TCRs
exhibited a range of structural avidities, and all were of lower
avidity than the HIV-specific TCR 1803 studied for compari-
son. While the functional avidities of the three IGRP-specific
TCRs did not correlate strictly with the measured structural
avidities, all were reduced compared to the functional avidity
observed for the HIV-specific TCR. This is perhaps not sur-
prising, as it is unlikely that T cells bearing high-affinity
autoreactive TCRs would escape negative selection in the
thymus [51]. It is becoming clear that autoreactive TCRs in
both mice and humans often exhibit low avidity, either
because of the TCR itself (as in our work) or because its
cognate peptide binds poorly to MHC [52–59]. It is not
unusual for autoreactive T cells to exhibit responses only to
relatively high concentrations of peptide in vitro (compared
to anti-viral T cells, for example) [52,56,57,59]. Some of
these T cells are nonetheless pathogenic, presumably because
the local peptide concentration in the target organ is high
[60], or because the peptide is modified there in a way that
improves recognition [61]. The relatively high tetramer
avidity values for the IGRP-specific TCRs, the poor tetramer
staining observed in the absence of dasatinib for TCR 7 (and,
to a lesser extent, FSB) and the reduced functional avidities
compared to the anti-viral TCR support the autoreactive
nature of our TCRs and emphasize some of the challenges
inherent in working with autoreactive TCRs. TCR 7 is of par-
ticular interest, because its CDR3β loop is unusually long (19
residues). It is tempting to speculate that a loop of this length
may impair the formation of intimate contacts between the
TCR and the pMHC and, in so doing, may account for the
poor tetramer staining and low functional avidity observed
for this autoreactive TCR.
Another characteristic that has been reported for
autoreactive T cells is antigenic recognition promiscuity
(cross-reactivity) [62–69]. Our results show that this prop-
erty, exemplified by TCR 32, can also be studied using
lentiviral transduction of T cells. TCR 32 had the highest
structural avidity of the three TCRs examined here (as
measured by tetramer avidity); however, it was difficult to
document a functional peptide-specific response from
transduced cells due to its robust cross-reaction to human
cell lines expressing HLA-A2 and used as APC. Apparently,
in addition to recognizing IGRP265–273/HLA-A2, TCR 32 also
responds to one or more endogenous peptides presented by
HLA-A2 in these cell lines. When murine HLA-A2-positive
DCs were used as APC, the stimulation in the absence of
exogenous peptide was considerably reduced, but still
present. Surprisingly, however, the peptide-specific response
was quite low and required a high peptide concentration for
detection. Taken together, these data suggest not only that
TCR 32 is promiscuous, but also that one of its peptide
ligands may be an antagonist [70] that can dampen its
response to IGRP265–273. Alternatively, it is possible that the
binding characteristics of TCR 32 to IGRP265–273/HLA-A2 are
not suitable to elicit a strong functional response [71].
These results illustrate that careful in-vitro analysis of can-
didate TCRs, as performed here, is necessary before under-
taking in-vivo experiments, because tetramer binding does
not guarantee a measurable functional response to peptide.
Interestingly, we observed that FSB, isolated from a
healthy donor, was the most functionally active of the three
TCRs. This finding suggests that useful islet-specific human
TCRs need not be derived from diabetic patients, while also
Table 2. Human cell engraftment in NSG-A2 mice*.
Site
hCD45-positive cells [% of (hCD45 + mCD45)] hCD8-positive cells (% of hCD45)† GFP-positive cells (% of hCD8)‡
Untransduced FSB-transduced Untransduced FSB-transduced FSB-transduced
Blood
Week 1 0·2 ± 0·2 (6) 0·2 ± 0·3 (5)§ n.d. n.d. n.d.
Week 2 0·5 ± 0·6 (6) 0·7 ± 0·6 (5) 61 ± 29 (3) 33 ± 32 (3) 26 ± 27 (3)
Week 3 7·2 ± 14 (6) 8·0 ± 6·4 (5) 81 ± 12 (2) 47 ± 6·0 (4) 11 ± 10 (4)
Week 4 14 ± 16 (6) 22 ± 15 (5) 64 ± 20 (5) 39 ± 9·7 (5) 4·6 ± 3·4 (5)
Week 5 37 ± 34 (6) 52 ± 16 (5) 61 ± 22 (6) 31 ± 14 (5) 1·5 ± 1·4 (5)
Spleen 57 ± 29 (6) 70 ± 14 (5) 54 ± 20 (6) 32 ± 16 (5) 1·1 ± 1·1 (5)
Pancreas 44 ± 35 (6) 66 ± 16 (5) 51 ± 22 (6) 32 ± 12 (5) 1·9 ± 1·7 (5)
*Untransduced or T cell receptor (TCR) FSB lentivirus-transduced human leucocyte antigen (HLA)-A2+ human CD8 T cells (4 × 106) were com-
bined with CD8 T cell-depleted peripheral blood monunclear cells (PBMC) from the same donor (8 × 106) and transferred via tail vein into HLA-A2-
transgenic non-obese diabetic (NOD)-severe combined immunodeficient (SCID) interleukin (IL)-2rγ null (NSG-A2) mice. Blood was taken weekly
from the tail starting at week 1 and analysed for engraftment by flow cytometry. At week 5, mice were killed and blood, spleen and pancreas were ana-
lysed for engraftment. Numbers of mice are indicated in parentheses. Sample fluorescence activated cell sorter (FACS) plots are shown in Fig. 6a. n.d.,
not determined. †Expressed as a % of hCD45-positive cells. Mice having a hCD45-positive cell percentage less than 0·5% for a given time-point were
excluded from subsequent analysis for that time-point. ‡Expressed as a % of hCD8-positive cells. §A sixth mouse had a splenic hCD45-positive cell fre-
quency of less than 1% at week 5 and was excluded from further analysis.
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Fig. 6. Transduced human CD8 T cells remain detectable and functional 5 weeks after transfer to human leucocyte antigen (HLA)-A2-transgenic
non-obese diabetic (NOD)-severe combined immunodeficient (SCID) interleukin (IL)-2rγ null (NSG-A2) mice. NSG-A2 mice were injected
intravenously with 4 × 106 untransduced, FSB-transduced, or 1803-transduced human CD8 T cells in combination with 8 × 106 CD8-depleted
peripheral blood mononucleaer cells (PBMC). Blood samples were taken weekly from 1 to 5 weeks after transfer and analysed by flow cytometry.
Spleen and pancreas were analysed similarly at 5 weeks post-transfer. (a) Engraftment of a representative FSB recipient mouse (middle panels), with
an NSG-A2 mouse that did not receive human cells shown for comparison (top panels). Top and middle panels, total hCD45+mCD45− cell
engraftment (% of total cells is shown). Bottom panels, engraftment of green fluorescent protein (GFP)+ FSB-transduced CD8 T cells (% of
hCD45+mCD45−hCD8+ cells is shown). Due to the necessity of analysing the time-points on different days, variations in fluorescence intensity were
observed. Summary data from all mice are shown in Table 2. (b) Pancreata from untransduced and FSB-transduced recipient mice were fixed
5 weeks after transfer, sectioned, and stained with aldehyde fuchsin. Representative images of islets from untransduced and FSB recipient mice are
shown. (c) Splenocytes from untransduced, 1803-transduced and FSB-transduced recipient mice were analysed for intracellular granzyme B
expression by flow cytometry 5 weeks after transfer. Left panel, granzyme B expression of untransduced hCD45+mCD45− cells. Middle and right
panels, granzyme B expression of hCD45+mCD45−hCD8+ cells from 1803 and FSB recipient mice.
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once again highlighting the need for rigorous in-vitro analy-
sis of TCRs.
Multiple antigen-specific therapies have demonstrated
potential for preventing diabetes development in NOD
mice by inducing deletion of β cell-specific CD8 T cells
[72–74]. We have found that delivery of β cell antigens to
DCs via the endocytic receptor DEC-205 can lead to the
deletion of both transferred [75] and endogenous CD8 T
cells [76] specific for the delivered antigen. Our ability to
generate human CD8 T cells specific for β cell antigens and
their survival in NSG-A2 mice will now allow such
deletional strategies to be explored in a system incorporat-
ing human T cells. This line of investigation does not
require that the recipient mice develop diabetes, as T cell
deletion in response to treatment can be monitored even in
the absence of overt disease by evaluating GFP expression.
However, our goal is to optimize our system further so that
diabetes is observed. The T cell clones from which the
TCRs 7, FSB and 32 were obtained originally were able to
lyse human β cells (data not shown), supporting their
potential diabetogenic nature. It is possible that we did not
observe diabetes upon transfer of transduced IGRP-specific
CD8 T cells to NSG-A2 mice because this single specificity
may be insufficient to cause disease. However, our experi-
mental design was based in part on our finding that trans-
fer to NOD-SCID recipients of cultured islet infiltrates
from 8·3 TCR (specific for H-2Kd/IGRP206–214)-transgenic
NOD mice induced diabetes in all recipients (data not
shown). These cultured infiltrates contained 98% CD8 T
cells and, of these, 80% were specific for IGRP206–214, sug-
gesting at least the possibility that a T cell population
highly enriched for CD8 T cells having a single specificity
can indeed transfer disease to an immunodeficient host.
However, our lentiviral transduction approach will allow
human CD8 T cells having multiple defined antigenic spe-
cificities to be engineered and if necessary transferred in
the future. Furthermore, we have found that human CD4 T
cells can also be engineered by lentiviral transduction to be
specific for β cell antigens (data not shown), suggesting the
possibility of simultaneously transferring β cell-specific
CD8 and CD4 T cells to NSG mice transgenic for human
class I and class II MHC molecules. The contribution of
CD4 T cells to islet pathology in such a model is suggested
by the recent report that insulitis was observed when
immortalized human CD4 T cells specific for HLA-DR4-
binding β cell peptides were transferred to NSG mice trans-
genic for HLA-DR4 [77].
In addition to the possible requirements for multiple
antigenic specificities or both CD8 and CD4 T cells, the
duration of our experiments may have been insufficient
for diabetes development to take place. We followed the
recipient mice for only 5 weeks after transfer of the engi-
neered IGRP-specific T cells, as a xenogeneic GvH disease
develops in NSG mice engrafted with human PBMC
within 4–5 weeks after transfer [15]. This GvH disease is
due largely to a T cell response to murine class I MHC
molecules, as NSG mice that are murine class I MHC-
deficient are relatively resistant to this disease [50]. Murine
class I-deficient NSG-A2 mice will probably be an
improved recipient for the engraftment of engineered β
cell-specific human CD8 T cells, as they will allow the
experimental duration to be extended. They should also
allow increased numbers of transduced CD8 T cells to be
transferred.
We demonstrate here for the first time, to our knowledge,
the ability to generate human islet-specific cytotoxic T cells
at will by TCR lentiviral transduction and their survival for
up to 5 weeks in NSG-A2 mice. We believe that this strategy
has the potential to allow for a better understanding of T1D
pathogenesis and the evaluation of antigen-specific thera-
pies. Our work highlights the difficulties in working with
autoreactive TCRs, including their low affinity for pMHC
and their propensity for promiscuity. However, our proof-
of-concept study none the less suggests broad applicability
of our approach to investigations concerning autoreactive T
cells involved in other human T cell-mediated autoimmune
diseases.
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